Lipid profile among PCSK9i-treated patients
| Total cholesterol (mmol/L) | LDL-C (mmol/L) | TG (mmol/L) | HDL-C (mmol/L) | |
| Baseline | 7.7 (1.6, 5.1–12.2) | 5.0 (1.6, 1.4–8.9) | 2.9 (1.7, 0.4–7.4)* | 1.4 (0.3, 0.8–2.2) |
| 3 months | 4.5 (1.4, 2.4–7.7) | 2.1 (1.3, 0.5–5.2) | 2.3 (1.0, 0.8–5.6)* | 1.4 (0.3, 0.9–2.1) |
| 12 months | 4.3 (1.2, 1.9–7.4) | 1.7 (1.1, 0.2–5.1) | 2.6 (1.1, 0.7–5.7)* | 1.4 (0.3, 0.9–2.5) |
N=40. Data are mean (SD, range).
*One patient was on fenofibrate, discontinuation of fenofibrate led to significant elevation of TG at 3 months and, therefore, fenofibrate was reinstated before the 12 months reading. This result was excluded from the graph.
HDL, high-density lipoprotein-cholesterol; LDL, low-density lipoprotein-cholesterol; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor; TG, triglycerides.